Clinical Trial Update: Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy in cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Peripheral Neuropathy

Drugs mentioned

• Alpha Lipoic Acid (alpha-lipoic acid)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific | Phase 3 | Status: COMPLETED